Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLOT-TB: Linezolid Dose Personalization Based on TDM in MDR-TB
NCT07477119Phase 4Recruiting
- Start
- Apr 2026
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of linezolid in multidrug-resistant tuberculosis (MDR-TB) (2 arms). Primary endpoint: Rate of linezolid related side effects at 6 months. Started Apr 2026; status: recruiting.
02
Drugs
linezolid
03
Conditions
multidrug-resistant tuberculosis (MDR-TB)
Beyond the preview
Go deeper on NCT07477119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07477119.